Page 44 - Trials Network News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cancer patients and the COVID-19 vaccines Clinicians, cancer patients and coronavirus researchers weigh in on vaccination safety, timing, allergy concerns and more January 14, 2021 • By Diane Mapes / Fred Hutch News Service Metastatic breast cancer patient and family doctor Dr. Carla Kakuta of Winters, California, receives her first COVID-19 shot, before heading off to cancer treatment. "I went straight from vaccination to the infusion center because I’m awesome like that," she wrote on Twitter. “I've been seeing patients in person through t...

Have been provided with the technical expertise of ViiV Healthcare and a financial incentive from Unitaid via CHAI, to accelerate the development, registration, manufacture and supply of generic... | January 15, 2021

Press release content from Globe Newswire. The AP news staff was not involved in its creation. GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development GeoVax, Inc.January 11, 2021 GMT Company Focused on Single-dose Vaccine Against Multiple COVID Strains ATLANTA, GA, Jan. 11, 2021 (GLOBE NEWSWIRE) --   via NewMediaWire  --  GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes o...

WHAT: A collaborative approach to treating opioid use disorder that relies heavily on community pharmacists is feasible and may increase adherence and participant satisfaction, according to a pilot study published today in Addiction. The study was supported by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, through the NIDA Center for the Clinical Trials Network. Most people with opioid use disorder who would benefit from medication do not receive it. Buprenorphine is a safe and effective medication that has been used in opioid addiction treatment for ...

January 6, 2021 Researchers at the  University of Maryland School of Medicine (UMSOM) will participate in a Phase 3 clinical trial of an investigational COVID-19 vaccine to protect against SARS-CoV-2, the coronavirus causing COVID-19 that continues to impact millions of people around the world. The clinical trial will test the safety and effectiveness of NVX-CoV2373, being developed by U.S. biotechnology company Novavax, Inc., based in Gaithersburg, MD. Clockwise from top left: Monica McArthur, Karen Kotloff, E. Albert Reece, and Kathleen Neuzil. The vaccine trial is being co...